Liquidia Technologies, Inc.
(NASDAQ : LQDA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc.
1.58%43.800.9%$908.93m
JNJJohnson & Johnson
1.58%136.070.6%$848.11m
MRKMerck & Co., Inc.
2.18%70.980.6%$587.27m
LLYEli Lilly and Company
0.17%110.811.0%$520.92m
ABBVAbbVie, Inc.
2.50%91.412.2%$505.16m
BMYBristol-Myers Squibb Company
-0.15%57.531.4%$344.83m
NVSNovartis AG Sponsored ADR
2.41%85.150.2%$175.88m
AZNAstraZeneca PLC Sponsored ADR
3.76%38.881.3%$144.62m
GSKGlaxoSmithKline plc Sponsored ADR
2.16%39.720.2%$87.61m
NVONovo Nordisk A/S Sponsored ADR Class B
2.33%43.290.1%$87.05m
SNYSanofi Sponsored ADR
1.85%44.240.2%$59.98m
LCILannett Company, Inc.
2.87%4.1337.0%$7.08m
AKTXAkari Therapeutics Plc Sponsored ADR
4.49%1.861.7%$0.16m
EPIXESSA Pharma Inc
-6.03%3.430.1%$0.04m

Company Profile

Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. The collaborates with leading pharmaceutical companies to apply its PRINT technology across a wide range of therapeutic areas, molecule types and routes of administration. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.